UNSPSC 51102909: Artesunate/Pyronaridine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP101. This VA Drug Class (AP101) classifies this compound as belonging to the group ANTIMALARIALS.

UNSPSC 51102909 Artesunate/Pyronaridine is a Commodity code that nominally describes antimalarial pharmaceuticals, but the recent state and local opportunities posted against it span emergency medical supplies, naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic pharmaceuticals through cooperative purchasing agreements—indicating a misalignment between the code's narrow product scope and how state and local jurisdictions are actually using it to tag pharmaceutical and medical supply procurement. State and local health departments, fire rescue divisions, and cooperative purchasing alliances are the primary issuing bodies driving activity under this code. The kinds of work being solicited include bulk procurement of emergency response medications and first aid consumables for municipal fire departments, state pharmacy benefit program design for direct manufacturer relationships, and multi-state cooperative pharmaceutical contracting covering both brand-name and generic drugs.

Recent opportunities show geographic spread across Florida, Texas, and Minnesota, with activity driven by county health systems (Seminole County, Florida's naloxone and drug deactivation systems procurement via IFB60459723LAS), state health agencies (Texas Health and Human Services Commission's RFI HHS0017013 for direct-to-manufacturer prescription programs, posted April 3, 2026), municipal fire and rescue services (City of Tampa's medical and first aid supplies IFB 26P00145, due March 13, 2026, with an estimated contract value of $700,000.00 and a 5 percent bid discount set-aside for certified Small Local Business Enterprises), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance RFP S1070000015802 for generic pharmaceuticals and OTC products, due March 26, 2026, covering Oregon and other participating jurisdictions). The Tampa procurement is sheltered exclusively for certified SLBEs with a maximum discount of $10,000. Activity is nascent and uneven—the Texas RFI represents early-stage market intelligence gathering rather than a formal competitive solicitation, and the code's mismatch with actual pharmaceutical procurement suggests that state and local buyers are applying it inconsistently across different categories of drugs and medical supplies.